ASLN
Closed
Aslan Pharmaceuticals Ltd Adr
0.6
+0.6 (0%)
Last Update: 16 Aug 2024 16:30:00
Yesterday: 0.
Day's Range: 0.6 - 0.6
Send
sign up or login to leave a comment!
When Written:
2.88
Aslan Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of cancer, inflammation, and other diseases. The company's lead product candidate, varlitinib, is an oral small molecule inhibitor of the human epidermal growth factor receptor family, which is being developed for the treatment of various solid tumors.
Aslan Pharmaceuticals is headquartered in Singapore and has operations in Taiwan and China. The company's American Depositary Receipts (ADRs) trade on the NASDAQ Global Market under the ticker symbol "ASLN." Each ADR represents five ordinary shares of Aslan Pharmaceuticals.
As of August 2021, Aslan Pharmaceuticals had a market capitalization of approximately $137 million. The company has a pipeline of other product candidates in various stages of development, including a potential treatment for acute respiratory distress syndrome (ARDS) and a novel immunotherapy for gastric cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Aslan Pharmaceuticals is headquartered in Singapore and has operations in Taiwan and China. The company's American Depositary Receipts (ADRs) trade on the NASDAQ Global Market under the ticker symbol "ASLN." Each ADR represents five ordinary shares of Aslan Pharmaceuticals.
As of August 2021, Aslan Pharmaceuticals had a market capitalization of approximately $137 million. The company has a pipeline of other product candidates in various stages of development, including a potential treatment for acute respiratory distress syndrome (ARDS) and a novel immunotherapy for gastric cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








